D&O Ongoing Disclosure Notice

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Oceania Healthcare Limited
Date this disclosure made:
20 June 2024
Date of last disclosure:
30 November 2023
Director or senior manager giving disclosure
Full name(s):
Alan Isaac
Name of listed issuer:
Oceania Healthcare Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Registered holder as trustee of
associated family trust
For that relevant interest-
Number held in class before acquisition or disposal:
206,099
Number held in class after acquisition or disposal:
256,099
Current registered holder(s):
Unknown
Registered holder(s) once transfers are registered:
Alan Raymond Isaac and Alasdair
Donald McBeth as trustees of the
Isaac Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative(if any):
N/A
The price specified in the terms of the derivative (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: one

Details of transactions requiring disclosure-
Date of transaction:12 June 2024
Nature of transaction:
On market acquisition of shares
Name of any other party or parties to the transaction (if known):on-market so unknown
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$26,500
Number of financial products to which the transaction related: 50,000
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:Ordinary shares
Nature of relevant interest:
Registered holder and beneficial
owner
For that relevant interest,-
Number held in class:138,787
Current registered holder(s):Alan Raymond Isaac
For a derivative relevant interest,-
Type of derivative:N/A
Class of quoted financial products:Ordinary shares
Nature of relevant interest:Holding by spouse
For that relevant interest,-
Number held in class:15,000
Current registered holder(s):Mary Isaac
For a derivative relevant interest,-
Type of derivative:N/A
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
N/A
A statement as to whether the derivative is cash settled or physically settled:
N/A
Maturity date of the derivative (if any):
N/A
Expiry date of the derivative (if any):
N/A
The price's specified terms (if any):
N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative:
N/A
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A

Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:N/A
Date of signature:N/A
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
20 June 2024
Name and title of authorised person:
Claire Fisher (Chief Legal and Risk
Officer)